TDM has been, almost exclusively, investigated for anti-TNF- therapy, and applied in IBD to a much greater extent than in other IMIDs
Together with the absence of symptoms associated with IGF-1-mediated effects such as fluid retention, tissue edema, or impaired glucose tolerance, these results demonstrate that AOD-9604 does not activate the growth hormone/IGF-1 pathway and therefore functions through an entirely appetite-independent mechanism
Users have reported faster recovery times and reduced inflammation, although comprehensive clinical trials in humans are still limited
medical research institutions
A typical nasal TB-500 protocol might use 500-1000mcg daily during loading phases, dropping to 250-500mcg daily for maintenance
doi: 10.12932/AP-011117-0188